1985607-66-6

Usage

Uses

Used in Pharmaceutical Industry:
1-amino-3-(benzyloxy)-4-oxo-1,4-dihydropyridine-2-carboxylic acid ethyl ester is used as a key intermediate in the synthesis of pharmaceutical drugs due to its capacity to be transformed into a variety of biologically active molecules. Its presence in the development pipeline underscores its importance in creating new therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 1-amino-3-(benzyloxy)-4-oxo-1,4-dihydropyridine-2-carboxylic acid ethyl ester is utilized as a precursor in the production of agrochemicals, contributing to the development of pesticides and other crop protection agents. Its versatility in chemical reactions allows for the creation of compounds that can address specific agricultural needs.
Used in Organic Synthesis:
As an intermediate in organic synthesis, 1-amino-3-(benzyloxy)-4-oxo-1,4-dihydropyridine-2-carboxylic acid ethyl ester is employed for its ability to participate in various chemical reactions, leading to the formation of a wide range of organic compounds. Its role in organic synthesis is crucial for the advancement of chemical research and the creation of novel chemical entities.

Upstream product

• 119736-16-2 3-(benzyloxy)-1-((tert-butoxycarbonyl)amino)-4-oxo-1,4-dihydropyridine-2-carboxylic acid ethyl ester 
• 1332855-94-3 3-(benzyloxy)-4-oxo-4H-pyran-2-carboxylate ethyl ester 

Downstream Products

• 1985605-59-1 (R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione 

Relevant academic research and scientific papers

Condensed polycyclic pyridone derivative and application thereof

The invention belongs to the field of medicines, and particularly relates to a fused polycyclic pyridone derivative as shown in a formula I, pharmaceutically acceptable salts, solvates, including hydrates, polycrystals, prodrugs, eutectics, tautomers and stereoisomers thereof, and application of the fused polycyclic pyridone derivative and the pharmaceutically acceptable salts, the solvates, the tautomers and the stereoisomers. Particularly, the compound provided by the invention can be used as an anti-influenza drug with a CEN inhibition effect.

Fused polycyclic pyridone derivative and application thereof

The invention belongs to the field of medicines, and particularly relates to a fused polycyclic pyridone derivative as shown I. Pharmaceutically acceptable salts, solvates, hydrates, N - oxides, polycrystals, cocrystals, tautomers, stereoisomers or mixtures or prodrugs thereof, and more particularly, compounds according to the invention can be used as anti-influenza drugs with CEN inhibitory action.

Condensed ring pyridone derivative as well as preparation method and application thereof

The invention discloses a condensed ring pyridone derivative as well as a preparation method and an application thereof. The condensed ring pyridone derivative is a compound shown in a formula I, or an optical isomer, an enantiomer, a diastereomer, a raceme or a racemic mixture thereof, or a solvate, a prodrug or pharmaceutically acceptable salt thereof. The invention also discloses the application of the compound and a pharmaceutical composition containing the compound in preparation of drugs for preventing and/or treating viral infection diseases. The viral infectious disease is a disease caused by a virus having a cap-dependent endonuclease, and more specifically, an infectious disease caused by influenza A or influenza B.

INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF

Disclosed are a compound as shown in formula (I) as an influenza virus replication inhibitor and a preparation method therefor, a pharmaceutical composition comprising the compound and the use of the compound and pharmaceutical composition thereof in the treatment of influenza.

Cap dependent endonuclease inhibitor and use thereof

The invention discloses a cap dependent endonuclease inhibitor and an application thereof. The dependent endonuclease inhibitor contains a heterocyclic compound represented by the following formulae (I), (II) and (III), or a pharmaceutically acceptable salt, solvate or crystal thereof. The compound disclosed by the invention can be used for preparing medicines for preventing or treating infectiousdiseases of mammals, and particularly can be used for preparing medicines for preventing or treating and alleviating and/or treating orthomyxovirus infection (such as influenza A viruses, influenza Bviruses and influenza C viruses).

A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG

A medicament characterized in that (A) a compound represented by the formula (I): its pharmaceutically acceptable salt, or a solvate thereof, wherein P is hydrogen or a group to form a prodrug; A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is each independently CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A4 is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A are each independently hydrogen, halogen, alkyl, or the like; R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle; n is any integer of 1 to 2; and R1 is or the like, is combined with (B) compound(s) having an anti-influenza activity, its pharmaceutically acceptable salt or a solvate thereof and/or an antibody having anti-influenza activity, is useful for treating or preventing influenza.

Crystal form of pyridone derivative and preparation method and application thereof

The present application provides (((R)-12'-((S)-7,8-difluoro-6, 11-dihydrodibenzo[b,e]thiepan-11-yl)-6',8'-dioxo-6',8',12',12a'stetrahydro-1'H-,4'H-spiro [cyclopropane-1, 3'-[1, 4] oxazepino [3, 4-c]pyridine, and [2, 1-f] [1, 2, 4] triazine]-7'-yl) oxy) methyl methyl carbonate, i.e., compound of formula (1) or a solvate thereof and a preparation method of the crystal. The crystal comprises an A-type crystal form, a B-type crystal form, a C-type crystal form, a D-type crystal form, an E-type crystal form, an F-type crystal form and a single crystal. The crystal of the compound shown in the formula (1) or the solvate thereof can be independently used for clinical treatment or combined medication with other anti-flu drugs such as neuraminidase inhibitors, nucleoside drugs and PB2 inhibitors,flu patients can be clinically and rapidly cured, and compared with existing pyridone derivatives, the pyridone derivative has the advantages that the cost is low, and the application prospect is broad. The pharmaceutical composition not only has very good activity, but also has good bioavailability. Meanwhile, the stability, hygroscopicity, storability and the like of the crystals meet the medicinal requirements.

Polycyclic pyridone compound as well as pharmaceutical composition and application thereof

The invention provides a polycyclic pyridone compound as well as pharmaceutical composition and an application thereof. Specifically, the polycyclic pyridone compound is a compound shown as the formula (I) or pharmaceutically acceptable salt, solvate or hydrate of the compound. The compound can be used for preparing drugs for preventing or treating infectious diseases of mammals, and is particularly used for preparing drugs for preventing, treating, relieving and/or treating orthomyxovirus infection such as influenza A virus, influenza B virus and influenza C virus.

Substituted polycyclic pyridone derivative prodrug containing pharmaceutical composition

The present invention provides a pharmaceutical composition containing the following compound having antiviral action:P is hydrogen or a group to form a prodrug.

Substituted polycyclic carbamoyl pyridone derivative and its prodrug (by machine translation)

The invention discloses a group of substituted polycyclic carbamoyl pyridone derivative and its prodrug and its deuterated compounds, and their use as against influenza virus 5' cap structure (CAP) dependent endo enzyme activity inhibitors, for treating influenza virus caused by use of the common cold. The invention also comprising a pharmaceutically acceptable carrier with the combination of the compound of the present invention composition, and the use of the composition to inhibit the influenza virus propagation method. (by machine translation)